key: cord-0729056-sh6o4giv authors: Pieralice, Silvia; D’Onofrio, Luca; Pozzilli, Paolo; Buzzetti, Raffaella title: Third dose of COVID‐19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy date: 2022-04-30 journal: Diabetes Metab Res Rev DOI: 10.1002/dmrr.3533 sha: f8ab8fbaeb4f6ce3cf080217d03fee68bf70ab19 doc_id: 729056 cord_uid: sh6o4giv Few studies conducted until now point out to an impaired immune response following Sars-Cov2 vaccine in patients with diabetes. Persistent hyperglycaemia seems to worsen patients' prognosis with COVID-19, therefore the question arises whether poor glycaemic control may be correlated to the level of antibody response and to the ensuing protection after the administration of COVID-19 vaccine. Recent evidence suggests that poor metabolic control has a detrimental effect on vaccine's efficacy. The short-term use of continuous glucose monitoring before and soon after COVID-19 vaccination may represent a cost-effective option for a highly protective immune outcome in diabetic patients. This approach should be applied now on the occasion of administering the 3rd vaccine's dose. This article is protected by copyright. All rights reserved. Coronavirus (COVID-19) disease is usually characterised by poor prognosis in patients with diabetes implying that mitigation of the COVID-19 pandemic risk becomes a priority in patients with type 1 (T1D) or type 2 (T2D) diabetes. 1 Despite that COVID-19 vaccination represents the most powerful tool to mitigate COVID-19 disease, multiple unresolved issues with regard to the efficacy and durability of COVID-19 vaccine in patients with diabetes still remain unsolved. A recent systematic review summarises the main evidence of vaccine safety and effectiveness in adult patients with diabetes. 2 The authors underline that, although age was one of the most influencing factors in COVID-19 immune response to the vaccine, older people with diabetes showed even lower antibody response compared to people in the same age group without diabetes. However, this reduced effect of vaccine in patients with diabetes was minimised when they were vaccinated at the time of good glycaemic control. 2 This topic rises as central in the vaccination efforts against SARS-Cov-2 in diabetes. The few studies conducted until now point out the impaired immune response towards SARS-Cov-2 vaccination in affected patients. Interestingly, a recent study highlighted the presence of lower antibody response to COVID-19 vaccination both in T1D and T2D. 3 However, given the fact that persistent hyperglycaemia seems to worsen patients' prognosis to COVID-19, 4 the question arises whether the poor glycaemic control may be correlated to the level of antibody response and to the ensuing protection after COVID-19 vaccination. In a study conducted to assess the immune response after BNT162b2 vaccine in 374 Japanese health workers, after univariate and multivariate regression analysis, HbA1c ≥ 6.5% was associated with a lower immune response. 5 Other than the impact of glucose control, an impairment in cellular immune response could also have an effect on the impaired COVID-19 vaccine response in people with diabetes. Data from nursing homes' residents in Belgium showed that the presence of diabetes was associated with lower cellular immunogenicity as measured by secretion of IFN-γ. 7 On the other side, reduction of blood glucose following a restriction in caloric intake in obese subjects correlates with increased IFN-γ. 8 Concerns also exist about vaccine-induced dysglycaemia among people with T1D and T2D. Thus, pro-inflammatory cytokines resulting from vaccination may reduce insulin sensitivity, potentially deteriorating glucose control. 9 Further studies are urgently needed to investigate the efficacy of SARS-Cov-2 vaccination in people with diabetes with the major focus on the improvement of glycaemic control to potentiate the vaccine effect. Although data with regard to glycaemic control in response to COVID-19 immunisation are still limited, a recent sub-study of the Diabetes Mellitus Study) made some interesting observations. Glucose managing technologies such as "continuous" and "flash" monitoring systems (CGM, FGM) have been shown to improve glycaemic control and to reduce glucose variability in patients with T1D and T2D. 15 These technologies could help diabetologists to optimise diabetes therapy with the aim to improve metabolic control in preparation for vaccine administration. 16 In this perspective, the short-term use of CGM or FGM devices on the occasion of the third dose of COVID-19 vaccine's administration may represent a cost-effective option for disease management in patients with diabetes. The authors would like to thank Centro Internazionale Studi Diabete, a no-profit Association which has supported over the years our research in diabetes. The authors declare no conflict of interest pertinent to the present commentary. All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines). Silvia Pieralice and Luca D'Onofrio -conceptualisation, writing, review and editing of the manuscript; Raffaella Buzzetti and Paolo Pozzilli -conceptual guidance, critical revision and editing of the manuscript. All authors read, commented, and approved the final version of the manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0003-3905-0139 Paolo Pozzilli https://orcid.org/0000-0001-5090-636X Raffaella Buzzetti https://orcid.org/0000-0003-1490-6041 The peer review history for this article is available at https://publons. com/publon/10.1002/dmrr.3533. Diabetes is a risk factor for the progression and prognosis of COVID-19 Assessing vaccine protection for older adults with diabetes: a systematic review BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers Outcomes in patients with hyperglycemia affected by Covid-19: can we do more on Glycemic control? Diabetes Care The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents Rapid weight loss, central obesity improvement and blood glucose reduction are associated with a stronger adaptive immune response following COVID-19 mRNA vaccine Clinical management of diabetes Mellitus in the Era of COVID-19: practical issues, peculiarities and Concerns Short-term safety profile of Sars-Cov2 vaccination on glucose control: continuous glucose monitoring data in people with autoimmune diabetes Impact of COVID-19 vaccination on glycemia in individuals with type 1 and type 2 diabetes: substudy of the COVAC-DM study The effect of hyperglycemia and hypoglycemia on glucose transport and expression of glucose transporters in human lymphocytes B and T: an in vitro study B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies Acute hyperglycaemic crisis after vaccination against COVID-19: a case series International Consensus on use of continuous glucose monitoring Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes